Back to Treatments

Treatment

Gemcitabine + Cisplatin (for recurrent/metastatic NPC)

1
Conditions
21
Trials
7,000
Participants
25%
Average Safety

Condition Evidence

Nasopharynx cancer

21 trials · 7,000 participants

75% effectiveness · 25% safety
Gemcitabine + Cisplatin (for recurrent/metastatic NPC) | DFDA